Cardinal Health, Inc. vs ICICI Bank Limited: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and ICICI Bank Limited across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating ICICI Bank Limited, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and ICICI Bank Limited is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against ~$23B for ICICI Bank Limited, while their respective market capitalizations stand at $56.0B and $100.0B. Cardinal Health, Inc. is headquartered in United States and ICICI Bank Limited in India, and those different home markets shape how each company competes.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

ICICI Bank Limited: ICICI Bank is India's second-largest private-sector bank, headquartered at Bandra Kurla Complex in Mumbai with its registered office in Vadodara. It serves retail, small-business, rural, corporate, and NRI customers through branches, ATMs, and digital channels, and it controls a group that includes ICICI Prudential Life Insurance, ICICI Lombard General Insurance, ICICI Prudential Asset Management, and ICICI Securities. With a market value of about Rs 9.4 lakh crore in late September 2026, it trails only HDFC Bank among private lenders.

Cardinal Health, Inc. and ICICI Bank Limited pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and ICICI Bank Limited.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

ICICI Bank Limited business model: ICICI Bank makes money mainly from net interest income: the gap between what it earns on loans and investments and what it pays on deposits and borrowings. Net interest income was Rs 22,979 crore in Q4 FY2026 alone and Rs 24,384 crore in Q1 FY2027, with a 4.32% FY2026 net interest margin. Fee income from cards, payments, wealth products, trade, and transaction banking is the second engine; fees grew 23.5% year on year in Q1 FY2027. The loan book is spread across retail (mortgages, auto, personal loans, cards), business banking for small firms, rural lending, and corporate banking. Group companies in life and general insurance, asset management, and brokerage add consolidated profit and cross-sell opportunities.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of ICICI Bank Limited.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

ICICI Bank Limited competitive advantage: ICICI Bank's edge is a combination of low-cost deposits, strong underwriting data, and distribution. Net NPAs were 0.33% at March 2026 and 0.35% at June 2026, with about Rs 131 billion of contingency provisions held on top of specific provisions. That buffer lets the bank grow loans without the provisioning shocks that hit it in 2015-2018. Its digital apps, corporate salary relationships, and group insurance and asset-management businesses also let it sell several products to the same customer.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and ICICI Bank Limited each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

ICICI Bank Limited growth strategy: Management frames its strategy as 'risk-calibrated core operating profit' growth. In FY2026 that meant leaning into segments growing faster than retail: total advances rose 15.8%, business banking 24.4%, and rural lending 25.6%, while retail loans grew 9.5% as the bank slowed unsecured credit. Digital platforms such as iMobile and InstaBIZ are used to cut servicing costs and widen cross-sell. The workforce fell by 5,148 permanent staff in FY2026 to 124,029, showing more automation even as branches expanded. Deposit gathering, especially current and savings balances, remains the constraint on loan growth.

A closer look at the financial trajectory of Cardinal Health, Inc. and ICICI Bank Limited rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

ICICI Bank Limited: ICICI Bank's finances moved from crisis to steady compounding over a decade. Bad corporate loans to infrastructure, power, and steel projects drove a non-performing asset surge between 2015 and 2018. After Sandeep Bakhshi became CEO in October 2018, the bank cut concentrated corporate exposure and rebuilt around granular retail and business lending. Standalone net profit reached Rs 47,227 crore in FY2025 and Rs 50,146.6 crore in FY2026, a 6.2% rise as margins held at 4.32%. Profit growth picked up again in Q1 FY2027 to 15.9% (Rs 14,805 crore), helped by 12.7% net interest income growth, 23.5% fee growth, and lower provisions. Consolidated Q1 FY2027 profit was about Rs 15,440 crore.